← Leaderboards
David S Metzger
University Of Pennsylvania
$45,509,531
Attributed
$49,696,476
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,441,636 · 18
CDC$2,239,250 · 1
By mechanism
U01$25,491,534 · 2
P30$14,842,883 · 10
R01$12,626,961 · 4
UM1$1,222,924 · 1
M01$496,584 · 2
Top collaborators
- Luis J. Montaner6 shared
- Kelly L Jordan-Sciutto4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Van My Ta Park$13,798,842
- Gyungah Jun$5,317,894
- Helena Chang Chui$16,982,623
- Li-San Wang$75,130,455
- James R McKay$19,797,907
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelProgramsCollaborationsHiv InfectionsAcquired Immunodeficiency SyndromeBehavioralCommunitiesFundingResourcesTrainingServicesDesignPhiladelphiaLinkEvaluationInnovationInternationalMentorsBiologicalUniversitiesClinical ResearchAwardParticipantAids/Hiv Problem
Grant awards (77)
Community Research & Engagement Core$237,529
P30 · FY2025 · AI · contact PI
Developmental Core B$199,878
P30 · FY2025 · MH · contact PI
Administrative Core A$169,755
P30 · FY2025 · MH · contact PI
Penn Mental Health AIDS Research Center$1,735,545
P30 · FY2024 · MH · contact PI
Administrative Core A$539,203
P30 · FY2024 · MH · contact PI
Community Research & Engagement Core$252,176
P30 · FY2024 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,621,237
R01 · FY2023 · DA
Penn Mental Health AIDS Research Center$1,499,680
P30 · FY2023 · MH · contact PI
Developmental Core B$351,410
P30 · FY2023 · MH · contact PI
Administrative Core A$298,206
P30 · FY2023 · MH · contact PI
Prevention Science & Community Engagement Core$254,266
P30 · FY2023 · AI · contact PI
Administrative Core A$243,750
P30 · FY2023 · MH · contact PI
Penn Mental Health AIDS Research Center$243,750
P30 · FY2023 · MH · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,652,477
R01 · FY2022 · DA
Penn mental health AIDS research center$1,505,435
P30 · FY2022 · MH · contact PI
Core B: Developmental core$453,364
P30 · FY2022 · MH · contact PI
Prevention Science & Community Engagement Core$214,912
P30 · FY2022 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,678,538
R01 · FY2021 · DA
Core B: Developmental core$439,072
P30 · FY2021 · MH · contact PI
Prevention Science & Community Engagement Core$215,819
P30 · FY2021 · AI · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,657,600
R01 · FY2020 · DA
Rapid initiation of buprenorphine/naloxone to optimize MAT utilization in Philadelphia$747,512
R01 · FY2020 · CE · contact PI
Prevention Science & Community Engagement Core$509,973
P30 · FY2020 · AI · contact PI
Core B: Developmental core$363,440
P30 · FY2020 · MH · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$1,248,932
R01 · FY2019 · DA
Rapid initiation of buprenorphine/naloxone to optimize MAT utilization in Philadelphia$746,191
R01 · FY2019 · CE · contact PI
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment$515,107
R01 · FY2019 · DA
Core B: Developmental core$363,990
P30 · FY2019 · MH · contact PI
Prevention Science & Community Engagement Core$215,274
P30 · FY2019 · AI · contact PI
Rapid initiation of buprenorphine/naloxone to optimize MAT utilization in Philadelphia$745,547
R01 · FY2018 · CE · contact PI
Core B: Developmental core$365,839
P30 · FY2018 · MH · contact PI
Developmental Core$409,899
P30 · FY2017 · MH · contact PI
Developmental Core$409,898
P30 · FY2016 · MH · contact PI
Developmental Core$412,002
P30 · FY2015 · MH · contact PI
Developmental Core$414,218
P30 · FY2014 · MH · contact PI
Penn prevention clinical trials unit$606,647
UM1 · FY2013 · AI · contact PI
Developmental Core$414,218
P30 · FY2013 · MH · contact PI
Behavioral & Social Sciences$217,824
P30 · FY2013 · AI · contact PI
Penn prevention clinical trials unit$616,277
UM1 · FY2012 · AI · contact PI
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta$286,029
R01 · FY2012 · DA · contact PI
Behavioral & Social Sciences$227,208
P30 · FY2012 · AI · contact PI
Penn prevention clinical trials unit$622,837
U01 · FY2011 · AI · contact PI
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta$302,544
R01 · FY2011 · DA · contact PI
Behavioral & Social Sciences$266,046
P30 · FY2011 · AI · contact PI
Penn prevention clinical trials unit$608,207
U01 · FY2010 · AI · contact PI
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta$314,406
R01 · FY2010 · DA · contact PI
Behavioral & Social Sciences$262,454
P30 · FY2010 · AI · contact PI
Penn prevention clinical trials unit$613,261
U01 · FY2009 · AI · contact PI
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta$368,625
R01 · FY2009 · DA · contact PI
Behavioral & Social Sciences$234,782
P30 · FY2009 · AI · contact PI
Penn prevention clinical trials unit$1,568,547
U01 · FY2008 · AI · contact PI
Core--Behavioral & Social Sciences Facility$215,709
P30 · FY2008 · AI · contact PI
Penn prevention clinical trials unit$1,228,585
U01 · FY2007 · AI · contact PI
Core--Behavioral & Social Sciences Facility$253,480
P30 · FY2007 · AI · contact PI
HIV PREVENTION TRIAL UNIT$1,884,755
U01 · FY2006 · AI · contact PI
Core--Behavioral & Social Sciences Facility$149,118
P30 · FY2006 · AI · contact PI
HIV PREVENTION TRIAL UNIT$6,551,905
U01 · FY2005 · AI
Core--Behavioral &Social Sciences Facility$144,832
P30 · FY2005 · AI
HIV PREVENTION TRIAL UNIT$4,196,356
U01 · FY2004 · AI
Core--Behavioral &Social Sciences Facility$138,929
P30 · FY2004 · AI
HIV PREVENTION TRIAL UNIT$1,878,519
U01 · FY2003 · AI
HIV PREVENTION TRIAL UNIT$3,550,212
U01 · FY2002 · AI
VAGINAL MICROBICIDE STUDY OF PMPA GEL: SAFETY STUDY$124,146
M01 · FY2002 · RR
HIVNET 020: TRIAL OF INVESTIGATIONAL VAGINAL MICROBICIDE PRO 2000/5 GEL$124,146
M01 · FY2002 · RR
HIV PREVENTION TRIAL UNIT$1,788,350
U01 · FY2001 · AI
VAGINAL MICROBICIDE STUDY OF PMPA GEL: SAFETY STUDY$124,146
M01 · FY2001 · RR
HIVNET 020: TRIAL OF INVESTIGATIONAL VAGINAL MICROBICIDE PRO 2000/5 GEL$124,146
M01 · FY2001 · RR
HIVNET 020: TRIAL OF INVESTIGATIONAL VAGINAL MICROBICIDE PRO 2000/5 GEL$0
M01 · FY2001 · RR
VAGINAL MICROBICIDE STUDY OF PMPA GEL: SAFETY STUDY$0
M01 · FY2001 · RR
HIV PREVENTION TRIAL UNIT$1,000,000
U01 · FY2000 · AI
EFFECTIVENESS OF MULTISITE NEP IN PREVENTING HIV &HBV$742,216
R01 · FY2000 · DA
VAGINAL MICROBICIDE STUDY OF PMPA GEL: SAFETY STUDY$0
M01 · FY2000 · RR
HIVNET 020: TRIAL OF INVESTIGATIONAL VAGINAL MICROBICIDE PRO 2000/5 GEL$0
M01 · FY2000 · RR
HIVNET 020: TRIAL OF INVESTIGATIONAL VAGINAL MICROBICIDE PRO 2000/5 GEL$0
M01 · FY2000 · RR
HIVNET 020: TRIAL OF INVESTIGATIONAL VAGINAL MICROBICIDE PRO 2000/5 GEL$0
M01 · FY2000 · RR
VAGINAL MICROBICIDE STUDY OF PMPA GEL: SAFETY STUDY$0
M01 · FY2000 · RR
VAGINAL MICROBICIDE STUDY OF PMPA GEL: SAFETY STUDY$0
M01 · FY2000 · RR